Home
News
Create
Screeners
Insights
Sudeep Pharma
615.
10
+1.10
(+0.18%)
Market Cap
₹6,947.47 Cr
PE Ratio
40.87
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+0.18%
1M
-3.73%
6M
-20.55%
1Y
-20.55%
5Y
-20.55%
View Company Insights
Latest news about Sudeep Pharma
Sudeep Pharma Limited Schedules Analyst and Investor Meetings for March 23, 2026
Mar 17, 2026
Sudeep Pharma Limited has scheduled analyst and institutional investor meetings for March 23, 2026 in Mumbai, starting from 12:00 pm onwards. The company filed this regulatory disclosure on March 17, 2026, under SEBI listing regulations, confirming that discussions will be limited to publicly available information with no unpublished price sensitive information to be shared. The meetings will be conducted in both one-on-one and group formats as part of the pharmaceutical company's investor relations activities.
Sudeep Pharma Submits Q3FY26 Earnings Call Transcript Following Strong Results
Feb 12, 2026
Sudeep Pharma Makes Q3FY26 Earnings Call Audio Recording Available Online
Feb 10, 2026
Sudeep Pharma Files Regulatory Notice for VP John Garcia's Resignation
Feb 05, 2026
Sudeep Pharma Subsidiary Acquires Gujarat Land Rights for ₹20.97 Crores Manufacturing Facility
Jan 22, 2026
More news about Sudeep Pharma
16
Jan 26
Sudeep Pharma Limited Updates CIN and Company Status Following Stock Exchange Listing
Sudeep Pharma Limited has successfully updated its Corporate Identification Number (CIN) from U24231GJ1989PLC013141 to L24231GJ1989PLC013141 on the MCA website following its listing on BSE and NSE on November 28, 2025. The company's status has been changed from unlisted to listed, with the updated master data showing authorized capital of ₹15.00 crores and paid-up capital of ₹11.29 crores. The pharmaceutical company, incorporated in 1989 and based in Gujarat, maintains active compliance status under ROC Ahmedabad jurisdiction.
22
Dec 25
Sudeep Pharma Submits Q2FY26 Earnings Call Audio Recording to Stock Exchanges
Sudeep Pharma Limited has completed its Q2FY26 earnings call and submitted the audio recording to stock exchanges in compliance with SEBI regulations. The call was held on December 22, 2025, to discuss performance for the quarter and half-year ended September 30, 2025, with the recording now available on the company's website for stakeholder access.
22
Dec 25
Sudeep Pharma Q2 Results: EBITDA Drops 12.6% to ₹55.5 Cr, Margin Shrinks
Sudeep Pharma Limited reported Q2 financial results showing revenue growth of 6.7% to ₹162.80 crores, but faced significant profitability pressures with EBITDA declining 12.6% to ₹55.50 crores and EBITDA margin compressing to 34.09% from 42.66% year-on-year. Net profit also decreased 6.2% to ₹45.70 crores, indicating operational challenges despite top-line growth.
20
Dec 25
Sudeep Pharma Completes Q2FY26 Results Publication in Newspapers
Sudeep Pharma Limited completed regulatory compliance by publishing its Q2FY26 financial results extract in newspapers on December 20, 2025. The company reported consolidated revenue of ₹16,266.62 crores and net profit of ₹4,677.82 crores, with detailed results available on stock exchanges and company website.
Sudeep Pharma
615.
10
+
1.
10
(+
0.
18
%)
1 Year Returns:
-20.55%
Industry Peers
Sun Pharmaceutical
1,693.60
(-
2.
02
%)
Divis Laboratories
5,856.50
(-
0.
85
%)
Torrent Pharmaceuticals
3,987.20
(-
3.
02
%)
Lupin
2,274.50
(-
0.
02
%)
Dr Reddys Laboratories
1,217.30
(+
0.
64
%)
Cipla
1,192.40
(-
0.
29
%)
Zydus Life Science
864.25
(+
0.
12
%)
Mankind Pharma
1,998.50
(-
0.
14
%)
Aurobindo Pharma
1,333.70
(-
0.
63
%)
Alkem Laboratories
5,258.00
(+
0.
26
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO